23 September 2026

Oncoinvent ASA – Disclosure of large shareholding

Reference is made to the stock exchange announcement by Oncoinvent ASA (the “Company”) on 22 September 2026 regarding the successful completion of a private placement and retail offering of 1,650,000 new shares at NOK 90.00 per share, and to the share lending agreement entered into between the Company, ABG Sundal Collier ASA and DNB Carnegie, a part of DNB Bank ASA (the “Managers”), Hadean and Linc AB (the “Share Lending Agreement”).

On 22 September 2026, Linc AB agreed to lend 555,362 shares in the Company to the Managers under the Share Lending Agreement, to facilitate delivery-versus-payment settlement of shares allocated in Tranche 1 and the Retail Offering. The share loan will be settled by re-delivery of an equivalent number of new shares following registration of the share capital increase with the Norwegian Register of Business Enterprises.

Before the share lending, Linc AB held 555,362 shares in the Company, corresponding to 12.40% of the shares and votes. Following the share lending, Linc AB holds 0 shares (0.00%) and a right to re-delivery of 555,362 shares, corresponding to 12.40% of the shares and votes (physically settled). The total position (shares and financial instruments) is unchanged at 12.40%.

Linc AB has been allocated 192,888 Offer Shares in the Private Placement. Following delivery of the allocated shares, Linc AB will hold 192,888 shares, corresponding to 3.15% of the Company’s 6,128,412 shares and votes following registration of the share capital increase. Following re-delivery of the lent shares, Linc AB will hold 748,250 shares, corresponding to 12.21% of the shares and votes.

This information is subject to the disclosure requirements pursuant to section 4-2 of the Norwegian Securities Trading Act.

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com



Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.

Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close